Conference Objectives
- Provide current and high-quality information on the latest developments in the management of lymphoproliferative disease
- Create collegial learning opportunities to enable clinicians to share real-world experience and to directly apply new insights to their practice
- Foster discussions that allow for the sharing of knowledge and experience among delegates and industry representatives
- Respond to emerging professional needs for specific and in-depth information on the latest therapies for lymphoproliferative disease in the Canadian market
Scientific Steering Committee
John Kuruvilla, MD, FRCPC
Peter Anglin, MD, MBA, FRCPC
Conference Agenda
Time
Session
Speaker
7:00 AM
Breakfast (60 mins)
8:00 AM
Introduction & Welcome
Dr. John Kuruvilla & Dr. Peter Anglin
8:10 AM
What is the SOC for POD24 FL
Dr. Dai Chihara
MD Anderson Cancer Center
8:30 AM
BiTEs and CARTs in RR-FL
Dr. Ronan Foley
McMaster University
8:50 AM
Panel
9:05 AM
Overview of the Treatment of PTCL-NOS
Dr. Matthew Lunning
University of Nebraska Medical Center
9:25 AM
Management of Rare PTCL Subtypes
Dr. Anca Prica
Princess Margaret Cancer Centre
9:45 AM
Panel
10:00 AM
Health Break (15 mins)
10:15 AM
Evolving Primary Therapy Approaches in DLBCL
Dr. Jason Westin
MD Anderson Cancer Center
10:35 AM
What is new in CART for DLBCL
Dr. Jakub Svoboda
University of Pennsylvania
10:55 AM
Bispecific Antibodies in RR-DLBCL
Dr. Krish Patel
Swedish First Hill Hospital, Seattle, WA
11:15 AM
Panel
11:30 AM
Lunch (60 mins)
12:30 PM
The Shifting Sands of Primary Treatment of Advanced cHL
Dr. Ann LaCasce
Dana-Farber Cancer Institute
12:50 PM
Optimizing Treatment of RR-cHL
Dr. Michael Crump
Princess Margaret Cancer Centre
1:10 PM
Panel
1:25 PM
The Evolution of Primary Treatment in MCL
Dr. John Kuruvilla
Princess Margaret Cancer Centre
1:45 PM
Positioning Novel Therapy in RR-MCL
Dr. Kami Maddocks
Ohio State University Comprehensive Cancer Center
2:05 PM
Panel
2:20 PM
Health Break (15 mins)
2:35 PM
CLL Frontline Therapy: Fixed Duration vs. Treat to Progression
Dr. Abi Vijenthira
Princess Margaret Cancer Centre
2:55 PM
How to treat CLL after BTKi and BCL2i
Dr. Versha Banerji
CancerCare Manitoba
3:15 PM
Richter’s Syndrome: State-of-the-Art Management
Dr. Tanya Siddiqi
City of Hope National Medical Center, Duarte, CA
3:30 PM
Panel
3:45 PM
Closing Remarks
Dr. John Kuruvilla & Dr. Peter Anglin
4:00 PM
Dismissal
Our Sponsors
Leaders
Supporters
Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.
The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians and researchers across Canada. It features peer-reviewed articles that present robust clinical perspectives and practical insights into disease management.